Excited to share that Eilean Therapeutics, one of our portfolio companies that is focused on targeting escape mutations in hematological cancers, has been showcased at the “Artificial Intelligence for Early Drug Discovery” Conference! https://t.co/kdZKYjdeRD #drugdiscovery#AI
Happy to announce that together with @OrbiMed we will invest $28.5M in breakthrough #cancer programs of 4 innovative companies! Learn more https://t.co/CaTPVyX65l
Our member @SnapBioSci achieved a milestone in developing several promising small molecule lead candidates with an outstanding selectivity profile for treatment of Hepatocellular carcinoma (HCC) and Hepatoblastoma together with @ChemDiv & @TorreyPinesInv. https://t.co/eBVSeXO0NZ
Excited to welcome @SnapBioSci into our investment framework! Together with @ChemDiv, we hope to help advance their Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases - https://t.co/wuaiPp5Vuu #Cancer#autoimmunedisease#Collaboration